文献速递临床试验与 GCP

免疫抑制急性呼吸衰竭患者高流量鼻氧与标准氧疗随机对照试验研究方案

High-flow nasal oxygen vs. standard oxygen therapy in immunocompromised patients with acute respiratory failure: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2018-03-05

本研究为多中心、开放标签、优效性随机对照试验,在30个ICU纳入免疫抑制合并急性呼吸衰竭且氧疗≥6 L/min的成人患者,比较经鼻高流量氧疗(HFNO)与标准氧疗对第28天死亡率的影响。基于标准氧组预期死亡率30%、HFNO组20%、α=5%、把握度90%,每组需389例,共778例。

要点

  • 免疫抑制合并急性呼吸衰竭成人,氧疗≥6 L/min者可入选。
  • 主要结局为第28天死亡率,HFNO与标准氧疗头对头比较。
  • 计划每组389例、共778例,以检测死亡率30%降至20%的差异。

核心结论

  • HIGH研究旨在验证HFNO在免疫抑制急性呼吸衰竭患者中的生存获益。

研究设计与样本

  • 多中心、开放标签、随机对照优效性试验,在30个ICU开展,属GRRR-OH协作组。
  • 纳入标准为成人、已知免疫抑制、急性呼吸衰竭、氧疗≥6 L/min、患者或代理人签署知情同意。
  • 排除标准包括濒死、未获知情同意、高碳酸血症(PaCO2≥50 mmHg)、孤立性心源性肺水肿、妊娠或哺乳、妨碍鼻导管置入的解剖因素、无法国法定医保覆盖、术后第1至6天(术后第6天后发生ARF可纳入)。
  • 主要结局为第28天死亡率;样本量基于标准氧组预期死亡率30%、HFNO组20%、α=5%、把握度90%,每组389例、共778例。
  • 招募期预计30个月,最后纳入患者额外随访28天。

关键数值与推荐

  • 主要结局为第28天死亡率。
  • 次要结局包括插管率、舒适度、呼吸困难、呼吸频率、氧合、ICU住院时间及ICU获得性感染。
  • 样本量计算:标准氧组死亡率30%、HFNO组20%,α=5%,把握度90%,每组389例、共778例。
  • 纳入要求氧疗≥6 L/min;排除高碳酸血症PaCO2≥50 mmHg。

临床怎么用

  • 为免疫抑制急性呼吸衰竭患者选择HFNO或标准氧疗提供随机对照证据。

局限性

  • 为研究方案,尚无结局数据。
  • 开放标签设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute respiratory failure (ARF) is the leading reason for intensive care unit (ICU) admission in immunocompromised patients. High-flow nasal oxygen (HFNO) therapy is an alternative to standard oxygen. By providing warmed and humidified gas, HFNO allows the delivery of higher flow rates via nasal cannula devices, with FiO2 values of nearly 100%. Benefits include alleviation of dyspnea and discomfort, decreased respiratory distress and decreased mortality in unselected patients with acute hypoxemic respiratory failure. However, in preliminary reports, HFNO benefits are controversial in immunocompromised patients in whom it has never been properly evaluated. METHODS/DESIGN: This is a multicenter, open-label, randomized controlled superiority trial in 30 intensive care units, part of the Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique (GRRR-OH). Inclusion criteria will be: (1) adults, (2) known immunosuppression, (3) ARF, (4) oxygen therapy ≥ 6 L/min, (5) written informed consent from patient or proxy. Exclusion criteria will be: (1) imminent death (moribund patient), (2) no informed consent, (3) hypercapnia (PaCO2 ≥ 50 mmHg), (4) isolated cardiogenic pulmonary edema, (5) pregnancy or breastfeeding, (6) anatomical factors precluding insertion of a nasal cannula, (7) no coverage by the French statutory healthcare insurance system, and (8) post-surgical setting from day 1 to day 6 (patients with ARF occurring after day 6 of surgery can be included). The primary outcome measure is day-28 mortality. Secondary outcomes are intubation rate, comfort, dyspnea, respiratory rate, oxygenation, ICU length of stay, and ICU-acquired infections. Based on an expected 30% mortality rate in the standard oxygen group, and 20% in the HFNO group, error rate set at 5%, and a statistical power at 90%, 389 patients are required in each treatment group (778 patients overall). Recruitment period is estimated at 30 months, with 28 days of additional follow-up for the last included patient. DISCUSSION: The HIGH study will be the largest multicenter, randomized controlled trial seeking to demonstrate that survival benefits from HFNO reported in unselected patients also apply to a large immunocompromised population. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT02739451 . Registered on 15 April 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Azoulay E, Lemiale V, Mokart D, et al. High-flow nasal oxygen vs. standard oxygen therapy in immunocompromised patients with acute respiratory failure: study protocol for a randomized controlled trial. Trials. 2018. PMID: 29506579. doi:10.1186/s13063-018-2492-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。